BioNexus Gene Lab (BGLC) Competitors $0.23 -0.03 (-12.80%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BGLC vs. TOI, PMD, MRAI, BRTX, OPGN, KDLY, OTRK, MGRX, VSEE, and ATPCShould you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Oncology Institute (TOI), Psychemedics (PMD), Marpai (MRAI), BioRestorative Therapies (BRTX), OpGen (OPGN), Kindly MD (KDLY), Ontrak (OTRK), Mangoceuticals (MGRX), Vsee Health (VSEE), and Agape ATP (ATPC). These companies are all part of the "healthcare" industry. BioNexus Gene Lab vs. Oncology Institute Psychemedics Marpai BioRestorative Therapies OpGen Kindly MD Ontrak Mangoceuticals Vsee Health Agape ATP BioNexus Gene Lab (NASDAQ:BGLC) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Do analysts prefer BGLC or TOI? Oncology Institute has a consensus target price of $2.50, suggesting a potential upside of 1,089.91%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than BioNexus Gene Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncology Institute 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, BGLC or TOI? BioNexus Gene Lab has a beta of 6.55, meaning that its share price is 555% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Do institutionals and insiders believe in BGLC or TOI? 18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 2.0% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 9.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, BGLC or TOI? BioNexus Gene Lab has higher earnings, but lower revenue than Oncology Institute. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNexus Gene Lab$9.26M0.44-$2.63MN/AN/AOncology Institute$378.93M0.04-$83.07M-$0.78-0.27 Does the MarketBeat Community prefer BGLC or TOI? Oncology Institute received 4 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users. CompanyUnderperformOutperformBioNexus Gene LabN/AN/AOncology InstituteOutperform Votes466.67% Underperform Votes233.33% Is BGLC or TOI more profitable? BioNexus Gene Lab has a net margin of -10.17% compared to Oncology Institute's net margin of -17.63%. BioNexus Gene Lab's return on equity of -9.93% beat Oncology Institute's return on equity.Company Net Margins Return on Equity Return on Assets BioNexus Gene Lab-10.17% -9.93% -8.43% Oncology Institute -17.63%-186.83%-34.58% Does the media favor BGLC or TOI? In the previous week, Oncology Institute had 3 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 3 mentions for Oncology Institute and 0 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.00 beat Oncology Institute's score of -0.15 indicating that BioNexus Gene Lab is being referred to more favorably in the media. Company Overall Sentiment BioNexus Gene Lab Neutral Oncology Institute Neutral SummaryOncology Institute beats BioNexus Gene Lab on 8 of the 15 factors compared between the two stocks. Ad InvestorPlaceWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Get BioNexus Gene Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGLC vs. The Competition Export to ExcelMetricBioNexus Gene LabMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.72M$2.93B$5.14B$9.08BDividend YieldN/A15.63%5.09%4.23%P/E RatioN/A16.0289.7417.16Price / Sales0.44284.461,117.09117.04Price / CashN/A472.1143.1037.86Price / Book0.425.194.784.78Net Income-$2.63M-$32.86M$120.31M$225.60M7 Day Performance-12.00%-3.01%-1.92%-1.23%1 Month Performance-21.39%0.94%13.65%0.46%1 Year Performance-57.61%12.20%28.34%15.24% BioNexus Gene Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGLCBioNexus Gene LabN/A$0.23-12.8%N/A-59.5%$4.72M$9.26M0.0030Positive NewsGap UpHigh Trading VolumeTOIOncology Institute2.5251 of 5 stars$0.21-5.8%$2.50+1,090.5%-87.6%$15.87M$378.93M-0.29660PMDPsychemedics1.4065 of 5 stars$2.67-1.8%N/A-7.0%$15.73M$22.10M0.00140Insider TradeGap DownHigh Trading VolumeMRAIMarpaiN/A$1.11-11.2%$6.00+440.5%-49.6%$15.25M$34.87M-0.42150Gap DownBRTXBioRestorative Therapies3.455 of 5 stars$1.48+1.8%$18.00+1,119.3%-10.9%$10.22M$150,000.00-0.917OPGNOpGenN/A$1.07-3.6%N/A-82.7%$8.95M$3.42M0.00100Analyst ForecastNews CoverageGap DownKDLYKindly MDN/A$1.20-7.8%N/AN/A$7.16M$2.88M0.00N/AGap DownOTRKOntrak2.6135 of 5 stars$1.60-2.4%$45.00+2,712.5%-76.7%$6.75M$11.24M-0.15250Positive NewsMGRXMangoceuticals1.1755 of 5 stars$2.53-3.1%N/A-96.1%$6.29M$755,000.00-0.453News CoveragePositive NewsGap DownVSEEVsee HealthN/A$1.39-6.6%N/AN/A$5.01M$6.38M0.00N/ANews CoverageATPCAgape ATPN/A$1.24-13.3%N/A-89.2%$4.95M$1.35M-1.9640Positive NewsGap Down Related Companies and Tools Related Companies TOI Alternatives PMD Alternatives MRAI Alternatives BRTX Alternatives OPGN Alternatives KDLY Alternatives OTRK Alternatives MGRX Alternatives VSEE Alternatives ATPC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BGLC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
